MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc.

$9.5
0.27 (2.9%)
NASDAQ Capital Market
USD, US
Biotechnology

INKT Price Chart

Basic
Market Cap$37.1M
Price$9.5
52 Week Range4.56-19
Beta0.05
Margins
Gross Profit Margin116.10%
Operating Profit Margin0.12%
Net Profit Margin0.12%
Valuation (TTM)
P/E Ratio-27.25
Price to Sales Ratio-0.00
Price to Book Ratio-21.39
PEG Ratio-1.49

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

31

IPO Date

2021-10-15T00:00:00.000Z

Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Phone

212 994 8250

Address

149 Fifth Avenue, New York, NY, 10010, US

CIK

0001840229